高级检索
当前位置: 首页 > 详情页

A preliminary proteomic analysis of tear fluid in patients with high myopia

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Dept Ophthalmol, Shijiazhuang 050000, Hebei, Peoples R China [2]Fourth Hosp Hebei Med Univ, Dept Ophthalmol, Shijiazhuang 050000, Hebei, Peoples R China [3]Hebei Gen Hosp, Dept Gastroenterol, Shijiazhuang 050000, Hebei, Peoples R China [4]Beijing Puren Hosp, Dept Ophthalmol, Beijing 100010, Peoples R China [5]Hebei Gen Hosp, Dept Ophthalmol, Shijiazhuang 050000, Hebei, Peoples R China
出处:
ISSN:

关键词: High myopia Tear fluid Proteomics LC-MS/MS Differentially expressed proteins

摘要:
BackgroundUsing liquid chromatography-tandem mass spectrometry (LC-MS/MS) as a protein quantification technique for the analysis of the proteomic profile of myopia patient tear fluid, to clarify the role of dysregulated proteins in high myopia (HM) in order to provide a more thorough understanding of the molecular processes involved in the development of the disease.MethodsSchirmer strips were used to acquire the tear films from 20 subjects (10 high myopia patients and 10 control subjects). LC-MS/MS was utilized to identify the proteome profile of the tears in order to assess protein interrelationships utilizing bioinformatics.ResultsThe tear preparations from the HM group and the control group included a total of 1544 proteins. The expression of 79 proteins out of the identified ones differed significantly between the two groups. 51 proteins showed overexpression and 28 proteins showed downregulation. 15 differentially expressed proteins (DEPs) were enriched in metabolic pathways, 15 DEPs were enriched in extracellular exomes, and 5 DEPs were enriched in the complement and coagulation cascades pathway. Potentially important proteins and therapeutic targets in human HM include TTR and Antithrombin-III.ConclusionThe proteomic analysis of tear fluid in high myopia patients identifies key proteins and pathways involved in the disease, offering potential biomarkers for its pathogenesis and therapeutic targets.

基金:
语种:
WOS:
PubmedID:
中科院分区:
出版当年[2025]版:
大类 | 3 区 医学
小类 | 3 区 眼科学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 眼科学
JCR分区:
出版当年[2024]版:
Q3 OPHTHALMOLOGY
最新[2024]版:
Q3 OPHTHALMOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2025版] 出版当年五年平均 出版前一年[2024版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Dept Ophthalmol, Shijiazhuang 050000, Hebei, Peoples R China [2]Fourth Hosp Hebei Med Univ, Dept Ophthalmol, Shijiazhuang 050000, Hebei, Peoples R China
通讯作者:
通讯机构: [1]Hebei Med Univ, Dept Ophthalmol, Shijiazhuang 050000, Hebei, Peoples R China [5]Hebei Gen Hosp, Dept Ophthalmol, Shijiazhuang 050000, Hebei, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号